You are worth tens of billions before you come to the system?

Chapter 170 Incorporation into the medical insurance system
The next day, Lin Zitai made an appointment with Parks.

According to a report from Tiger Research, Novartis Group spent at least US$40 billion to rescue the market last night, and is very determined to boost the group's share price.

Although there is an endless stream of negative voices, Western public opinion is public opinion when it is of use, and it is nonsense when it is not.

Overnight, the market value of Novartis skyrocketed by US$233 billion, reaching a market value of hundreds of billions. Investors made their choice with their brains.

A smile appeared on Parks' face: "Mr. Lin, I wish us happy cooperation in advance, but we have a request."

"But it doesn't matter."

“The price difference between the selling price of new drugs in China and our agency’s pricing cannot exceed twice.”

Through Lin Zitai's behavior, it is not difficult to see that he is a complete nationalist.

Parks had reason to worry that Lin Zitai's prices were too high, leaving them with little money and a reputation for him.

Lin Zitai smiled calmly: "Mr. Parks, don't worry, the official selling price and the agency price will not exceed twice, but we are cooperating with the Medical Insurance Bureau, so you won't have to ask, right?"

Regarding the disparity in selling prices at home and abroad, they have already made plans. The official selling price in China is 2 yuan per bottle, and the external selling price is 4 yuan per bottle.Through cooperation with the Medical Insurance Bureau and through medical insurance subsidies, the cost has been reduced to less than 1 yuan.

"of course not."

Parks smiled. They were not as kind-hearted as Lin Zitai. As long as the income was decent, the life and death of the patients was none of their business.

Anyway, it is not just a matter of a day or two for pharmaceutical companies to be called vampires by the public. The wholesale price is [-] yuan, and they can sell it for [-] yuan or even higher.

After all, the agent for the new slow-grain drug of the Prince Group can be said to be facing the world's disapproval. European and American tariffs and drug supervision must be taken care of in all aspects, and the tax rate is at least 40%.

If they can't make a lot of money, wouldn't it be a waste of nearly $[-] billion in stock repurchases?

Pax paused and asked again: "Mr. Lin, we need an accurate date."

"When can the new drug pass the review of the China Food and Drug Administration? Or you can hand over the ingredient test report to us in advance. As long as the report of the drug is OK, we can guarantee that it will be put on the market within the next three months."

The ingredient testing reports of new slow-grain drugs are also one of the important reasons why they receive support from Congress.

Both Prince Pharmaceuticals and Military General Hospital Fangcang have very strict drug controls on new slow-grain drugs.

The amount of medicine each person takes every day is rationed, and there will be no more or less pills.

Instead, every time the medicine is taken, the caregiver will watch the patient take it with their own eyes to eliminate the possibility of the medicine leaking out.

Looking around the world, except for China, the only way for European and American countries to learn about new chronic-grain drugs is through the two children who recovered from the disease.

But the two children had long since checked over and over again, from bone marrow to cerebral fluid, from head to toe, but could not find out anything.

Only by opening up the European and American markets, allowing new slow-grain drugs to flow into their countries, and having a large number of samples can they carry out drug research and development.

Lin Zitai's smile remained unchanged: "Thanks to Mr. Parks for your trouble, the review process of our country's Food and Drug Administration is about to end."

"That's fine, that's fine."

Parks smiled and was not embarrassed. Business negotiations are actually digging holes for each other in advance of cooperation.

And testing is constantly digging holes. If the other party accidentally steps on the hole, they will only be inferior to others in strange skills.

In the afternoon of that day, on the first floor of Prince's Building, both parties held a joint press conference and signed a letter of intent for strategic cooperation.

This news not only means that new slow-grain drugs are about to go overseas, but also means that a Chinese pharmaceutical company has stepped forward and successfully broken the monopoly in the European and American pharmaceutical fields.

At 1 o'clock in the evening, the joint broadcast took [-] minute to introduce, and the wording was also very particular: one small step for Chinese pharmaceutical companies, one giant step for global medical history.

The next morning, Lin Zitai took a private plane and landed at Beijing's international airport.

Firstly, to determine the launch date of the new drug, and secondly, to negotiate with the General Administration of Medical Insurance to allow the new drug to enter the medical insurance system.

Dai Chunsheng from the State Food and Drug Administration came to greet him personally, and Lin Zitai was flattered by the high-level courtesy.

On their way to the General Administration of Medical Insurance, Dai Chunsheng smiled and said, "Mr. Lin, it's been so long since the military hospital's shelter was built, but you haven't seen it with your own eyes yet?" Lin Zitai coughed a few times and looked serious. Said: "We express 120% trust in Dean Zhao Hao."

He heard Dai Chunsheng's teasing. In order to avoid Zhao Hao, he did not dare to come to the capital for several months and only dared to let Su Jiayue come forward.

Who knew that when she was young, frivolous and ignorant, she wanted to fall in love with a beautiful girl without considering the consequences at all, but now she would have to deal with her old father.

Fortunately, it was the Military General Hospital and we didn't have many interactions with him. If Zhao Hao was sitting in Dai Chunsheng's position, Lin Zitai would really be able to die.

Dai Chunsheng smiled, clicked through, and talked about the specific approval date of the new slow-grain drug: "Mr. Lin, it is expected to be approved for marketing in early November this year."

At the same time, I also asked about academic journals.

Lin Zitai said: "We do have plans in this area. Our country is still lagging far behind the rest of the world in the field of medicine. We should cultivate more local talents."

The value-added tax on new drugs is very high, and the total of various taxes is almost 20%. Under the slogan of national justice, you may be able to obtain tax reductions.

There was a hint of appreciation in Dai Chunsheng's eyes, and he understood Lin Zitai's intention: "Xiao Lin, don't worry, the country will give full support to companies that dare to innovate."

This new type of medicine, Chronograin New Drug, is fully exempted from the 17% value-added tax on basic medicines for seven years, and only needs to pay a small amount of local urban construction tax, education surcharge, etc.

If the academic weekly needs to fill in basic papers, it can also connect to the data database of the Chinese Academy of Sciences, and the Academy can even help release paper tasks.

Academic weekly is a thankless project. If it can be done well, it will be of great benefit to the contemporary generation and will benefit the future. It can also export Chinese culture to the outside world.

Just like universities in various countries, English is almost a compulsory course for students, and it accounts for a large proportion of the curriculum, because the world's mainstream academic weekly magazines are all in English.

Although there are Chinese weekly magazines in China, they are just for the organization's own entertainment. To put it bluntly, they are just for academics to brush up their resumes, let alone go abroad, even Xiangjiang does not recognize them.

If the domestic pharmaceutical field wants to develop, it needs a responsible and powerful company to take the lead.

Lin Zitai didn't know whether to laugh or cry: "General Dai, you are putting a high hat on me. I'm afraid my small body can't stand it."

Dai Chunsheng laughed: "Can it be that we, Mr. Lin, can't afford to wear this hat?"

"I can afford to wear it, but I'm worried that the project will not progress smoothly."

Lin Zitai pointed out that foreign academic monopoly is a monopoly based on strength.On the other hand, the academic monopoly in the country is nothing but a monopoly based on the status of a tutor.

Some people who are engaged in academics are engaged in academics on the surface, but in fact they are dedicated to researching, gaining high positions, and defrauding funds all day long.

The emergence of a serious academic institution is blocking their financial path. It is estimated that smear and slander will be inevitable in the future.

A literati's pen is sharper than a steel knife, killing people without blood.

Dai Chunsheng was silent for a long time, but he could not refute: "I will report this to the relevant departments and rectify the bad academic atmosphere in the country."

The weekly run by Lin Zitai has the best chance of success because Cheng Zhiyu takes the lead and Ms. Tu also responds to join.

As long as the first relevant paper by the developer of a new slow-grain drug is published, it will definitely make the weekly famous.

He would never let a few mouse droppings spoil the whole pot of porridge.

Not long after, Dai Chunsheng brought Lin Zitai to the General Administration of Medical Insurance to discuss the entry of new slow-grain drugs into the medical insurance system.

Due to the signing of a price anchoring agreement with Novartis Group, the price of 2 yuan per bottle has been determined.

The General Administration of Medical Insurance said that they could bear 55% and lower the price to 9000 yuan per bottle, but the price was too expensive.

Each bottle can only be used by each patient for one month, and the monthly cost is 9000 yuan, which is still too much of a burden for ordinary people.

New slow-grain drugs can only cure early-stage patients, but for patients in the middle and late stages, the disease is still a long-term one.

Lin Zitai couldn't bear it, but he didn't make any more concessions: "Developing new drugs requires huge funds. We need to recover the costs first and then consider reducing prices later."

(End of this chapter)